FiercePharma

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further Reduced Blood Sugar in Patients With Type 2 Diabetes - Findings Presented at European Association for the Study of Diabetes ...
FierceBiotech

Press Release: DA Approves New Route of Administration for Sanofi-Aventis's Rapid-Acting Apidra

DA Approves New Route of Administration for Sanofi-Aventis's Rapid-Acting Apidra BRIDGEWATER, N.J., June 15 -- Sanofi-aventis announced today that following a review of a supplemental New Drug ...
FierceBiotech

FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen

BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...
Newswire

Sanofi-aventis: Adding Lantus(R) to Oral Antidiabetic Drug Therapy Further

PARIS, Sept. 20 /CNW/ - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting ...